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Background: This study aimed to determine whether single nucleotide polymorphisms (SNPs) in genes involved in
DNA repair or metabolism of taxanes or platinum could predict toxicity or response to first-line chemotherapy in
ovarian cancer.
Methods: Twenty-six selected SNPs in 18 genes were genotyped in 322 patients treated with first-line
paclitaxel-carboplatin or carboplatin mono-therapy. Genotypes were correlated with toxicity events (anemia,
neutropenia, thrombocytopenia, febrile neutropenia, neurotoxicity), use of growth factors and survival.
Results: The risk of anemia was increased for variant alleles of rs1128503 (ABCB1, C > T; p = 0.023, OR = 1.71,
95% CI = 1.07-2.71), rs363717 (ABCA1, A > G; p = 0.002, OR = 2.08, 95% CI = 1.32-3.27) and rs11615 (ERCC1, T > C;
p = 0.031, OR = 1.61, 95% CI = 1.04-2.50), while it was decreased for variant alleles of rs12762549 (ABCC2, C > G;
p = 0.004, OR = 0.51, 95% CI = 0.33-0.81). Likewise, increased risk of thrombocytopenia was associated with
rs4986910 (CYP3A4, T > C; p = 0.025, OR = 4.99, 95% CI = 1.22-20.31). No significant correlations were found for
neurotoxicity. Variant alleles of rs2073337 (ABCC2, A > G; p = 0.039, OR = 0.60, 95% CI = 0.37-0.98), rs1695
(ABCC1, A > G; p = 0.017, OR = 0.55, 95% CI 0.33-0.90) and rs1799793 (ERCC2, G > A; p = 0.042, OR = 0.63, 95%
CI 0.41-0.98) associated with the use of colony stimulating factors (CSF), while rs2074087 (ABCC1, G > C;
p = 0.011, OR = 2.09, 95% CI 1.18-3.68) correlated with use of erythropoiesis stimulating agents (ESAs).
Homozygous carriers of the rs1799793 (ERCC2, G > A) G-allele had a prolonged platinum-free interval
(p = 0.016).
Conclusions: Our data reveal significant correlations between genetic variants of transport, hepatic metabolism,
platinum related detoxification or DNA damage repair and toxicity or outcome in ovarian cancer.
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Ovarian cancer is the fifth most common cause of cancer
death in women and the leading cause of gynaecological
cancer-related death in the developed world [1]. Despite
optimization of debulking surgery and chemotherapy regi-
mens, the overall 5-year survival in advanced stage disease* Correspondence: sandrina.lambrechts@uzleuven.be
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unless otherwise stated.is only 29% [2]. The current standard first-line chemother-
apy is a combination of paclitaxel and carboplatin. This
treatment is associated with serious hematologic toxicities
including grade 3–4 anemia (incidence 4.3-6.6%), grade
3–4 thrombocytopenia (4.7-12.9%), grade 3–4 neutropenia
(37-89%), febrile neutropenia (2.3-8%) [3-6] and grade 2–4
peripheral neuropathies (32-36%), resulting in dose reduc-
tions, treatment delays and representing an important
physical, psychological and financial burden for the
patient and society. Inter-individual differences in both
toxicity and outcome related to treatment with paclitaxel-ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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for toxicity have been identified, such as elderly age
(≥65 years), poor performance status and poor nutritional
status [7]. Furthermore, tumor-related factors including
advanced stage at diagnosis, high-grade serous disease and
residual tumor after debulking surgery are associated with
poor survival. Genetic variability represents another po-
tential factor explaining this inter-individual variability.
Genes related to drug transport, metabolism, detoxifica-
tion and DNA repair could influence the cytotoxic effects
associated with chemotherapy, including those involved in
the transport (e.g., ABCB1, ABCC1, ABCC2, ABCG2, and
SLCO1B3) [8-24], hepatic metabolism (CYP3A4, CYP3A5,
CYP2C8, CYP1B1) [8-12,14,18,25-27] and pharmaco-
dynamics (e.g., MAPT, TUBB, TP53) [28,29] of pacli-
taxel. Likewise, genes involved in detoxification (e.g.,
GSTP1, GSTT1, GSTM1) [30-33] and base-excision
DNA repair (e.g., ERCC1, ERCC2, XRCC1) [34,35] have
previously been linked with cytotoxicity of platinum
agents. In particular, genetic variants in these genes,
which generally are supposed to reduce the function of
the affected gene, have been proposed to underlie the
inter-individual differences in chemotherapy related
hematologic and neurotoxicity. Likewise, variants in
other genes, including SLC12A6, SERPINB2, PPARD and
ICAM have been proposed to contribute to chemotherapy-
induced peripheral neurotoxicity [36]. Most studies identi-
fying these candidate genes, however, have been performed
in small study populations and were limited to testing only
a few variants. Consequently, most of the reported associ-
ations have failed to be replicated in subsequent large-
scale validation studies. Furthermore, most studies did not
correlate genotypes with detailed clinical toxicity data.
In the current study, we therefore aimed to assess
prior associations for 26 selected genetic variants in 18
genes, in a large cohort of 322 ovarian cancer patients
treated with paclitaxel-carboplatin combination therapy
or carboplatin mono-therapy of whom detailed clinical
toxicity data were available.
Methods
Study population
All ovarian cancer patients presenting in participating
hospitals of the Belgian and Luxembourg Gynaecological
Oncology Group (BGOG) were recruited for this study.
Collection of germ-line DNA and baseline patient charac-
teristics were collected for each patient. Disease character-
istics were recorded after histologic examination with
registration of tumor stage according to the International
Federation of Gynecology and Obstetrics (FIGO) classifi-
cation, residual disease after debulking surgery, measure-
ment of tumor size on computed tomography (CT) scans
and determination of cancer antigen 125 (CA125) before,
during and after chemotherapy. Response to treatmentand disease progression were evaluated based on radio-
logic examination according to the Response Evaluation
Criteria in Solid Tumors Group (RECIST) criteria [37].
Paclitaxel was administered at a starting dose of
175 mg/m2 and carboplatin at a starting area under the
plasma concentration-versus time curve (AUC) of
5–7 mg/ml/min, with possible dose reductions after
the occurrence of severe toxicity. During treatment,
the use of erythropoiesis stimulating agents (ESAs)
and colony stimulating factors (CSFs) was conform
to uniform institutional standards; ESAs are given during
treatment with chemotherapy in symptomatic patients
with a hemoglobin level below 11 g/dl while CSFs
are given if (1) neutropenia grade 4 (ANC <500/mm3) to-
gether with fever > 38°C or (2) neutropenia grade 4
(ANC < 500/mm3) during minimum 5 consecutive
days. Toxicity during chemotherapy was systematically
and routinely scored according to the Common Ter-
minology for Adverse Events (CTCAE) version 4.0.
Hematological toxicity was scored based on routinely
performed weekly complete blood counts during treat-
ment and before each cycle to determine the nadir of
anemia, neutropenia and thrombocytopenia of each
administered cycle, neurotoxicity was scored at each
clinical-physical examination before each cycle. The
scored toxicities for each patient together with all
events of neutropenic fever and use of growth factors
were systematically recorded in medical electronic re-
cords and for the purpose of the present study retro-
spectively collected by two independent investigators.
The highest grade of toxicity over all courses within a
patient was reported, if weekly performed blood counts
were not available for each administered cycle or if
neurotoxicity was not scored for every cycle, the pa-
tient was excluded from the analysis. The primary ob-
jective of this study was the correlation of genetic
variation with the occurrence of hematologic toxicity
or neurotoxicity in patients treated with first-line carbo-
platin with or without paclitaxel. Secondary objectives in-
cluded the relation between genetic variation and the
need for growth factors during treatment with chemother-
apy, platinum-free interval (PFI) defined as the time be-
tween the last first-line platinum dose and progression,
and overall survival (OS). Analyses for PFI and OS were
performed in the population receiving a combination of
carboplatin and paclitaxel (n = 266) with exclusion of the
more favorable prognostic population receiving carbopla-
tin alone, based on clinical prognostic parameters such as
FIGO stage, tumor grade and histological subtype. All in-
cluded patients provided written informed consent before
enrollment. The Medical Ethics Committee of the Leuven
University Hospitals approved the study (ML6541), serv-
ing as central site with the authority to approve the study
for all participating sites.
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We performed an extensive literature search before start
of enrolment to identify genes associated with treatment
outcome or toxicity after platinum and/or paclitaxel ad-
ministration [8-34,36]. We then selected common mis-
sense or synonymous mutations in these genes, as well
as a number of SNPs that were located in the promoter
region of these genes, but have previously been corre-
lated with toxicity after platinum. In addition, we se-
lected 5 additional SNPs previously associated with
thalidomide-related neuropathy to investigate their role
in repair mechanisms and inflammation in the periph-
eral nervous system leading to altered neurotoxicity, ra-
ther than having a thalidomide-specific contribution to
correlated neurotoxicity [36]. Genomic DNA was ex-
tracted from the leucocyte fraction of whole blood sam-
ples (Qiagen DNeasy blood and tissue kit). All selected
SNPs were genotyped using Sequenom MassARRAY
technology (Sequenom Inc., CA, USA), as reported pre-
viously [38]. Overall 26 SNPs in 18 genes (Table 1) were
genotyped with an individual call rate >95% and an over-
all success rate >98.5%. We genotyped 15 duplicate sam-
ples revealing a genotype accuracy exceeding 99%.
Statistical analysis
We calculated median values and inter-quartile ranges
for all continuous variables, while frequencies and
percentages were calculated for categorical variables.
Genotype frequencies were tested for Hardy-Weinberg
equilibrium using a 1°-of-freedom χ2-test and consid-
ered significant at P < 0.05. Each of the variants were
correlated with toxicity events (i.e., the primary object-
ive) using binary logistic regression, while assuming an
additive genotypic model. Per-allele odds ratios (OR)
and their respective 95% confidence intervals (CI) are
reported. Regression analyses were performed without
correction for covariates and after correction for relevant
covariates, including age and BMI at the time of treat-
ment, dose of carboplatin per cycle (AUC), number of
administered cycles and treatment regimen (paclitaxel/
carboplatin versus carboplatin alone). For anemia, an add-
itional covariate was included, i.e., use of ESAs, whereas
for neutropenia and febrile neutropenia, use of CSFs was
included as an additional covariate. Secondary objectives,
PFI and OS, were analyzed for 26 variants using Cox-
regression analysis, adjusted for age at diagnosis only or
fully adjusted for age at diagnosis, FIGO stage, tumor
grade, tumor histology and residual disease after debulk-
ing surgery and PFS and OS estimates were calculated
using Kaplan-Meier method. Additionally, we investigated
which of the variants could predict the need for ESAs or
CSFs during treatment. All tests were two-sided and
statistical significance was set at p = 0.05. The Bonferroni
p-value threshold correcting for the multiple testing of 26SNPs was p < 0.0019. Statistical analyses were performed
using SPSS version 19 (SPSS for Windows, Rel. 19.0.0.
2010. Chicago, Illinois, USA: SPSS Inc.)
Results
Study population
Between January 2009 and December 2011 (pre-specified
period of 2 years), we recruited 322 ovarian cancer pa-
tients treated with 3–6 cycles paclitaxel-carboplatin
combination therapy (n = 266) or 3–6 cycles carboplatin
mono-therapy (n = 56) (Additional file 1: Figure S1). Of
all recruited patients, 99% was Caucasian (Table 2).
Hematological toxicity was analyzed in 290 patients,
after exclusion of patients for which weekly blood exam-
inations were not available (n = 32). For neurotoxicity,
56 patients treated with carboplatin monotherapy were
excluded since the incidence of sensory neuropathy was
significantly lower in this population (p < 0.001). One pa-
tient with pre-existing sensory neuropathy before start
of chemotherapy was additionally excluded, bringing the
total number of patients eligible up to 265. For the sec-
ondary objectives, PFI and OS, all patients treated with
paclitaxel-carboplatin (n = 266) were included. Patient,
disease and toxicity characteristics are summarized in
Table 2. Briefly, grade 3–4 anemia was present in 57 pa-
tients (19.7%), grade 3–4 thrombocytopenia in 57 patients
(19.7%), grade 4 neutropenia in 202 patients (69.7%),
whereas only 23 patients (7.9%) presented with grade 3–4
febrile neutropenia. In the group of patients selected for
neurotoxicity analysis, 48 patients (18.1%) developed grade
2–3 sensory and none motor neuropathy following com-
bination treatment with paclitaxel-carboplatin. Minor al-
lele frequencies (MAF) were similar to those reported
previously in Caucasians and adhered to Hardy-Weinberg
equilibrium. Allele frequencies of all genotyped SNPs are
shown in Additional file 2: Table S1.
Association with anemia, thrombocytopenia, neutropenia
and sensory neuropathy
Among the 290 patients eligible for the hematological
toxicity analysis, we observed significant associations
for 5 variants (Table 3). In particular, rs1128503
(ABCB1, C > T), rs12762549 (ABCC2, C > G), rs363717
(ABCA1, A >G) and rs11615 (ERCC1, T > C) were signifi-
cantly associated with grade 3–4 anemia (p = 0.035, OR
1.58; p = 0.005, OR 0.55; p = 0.001, OR 1.31 and p = 0.024,
OR = 1.58). After correction for relevant covariates (as ex-
plained in the statistical methods), these variants were still
significantly associated with toxicity (p = 0.023, OR 1.71;
p = 0.004, OR 0.51; p = 0.002, OR 2.08; and p = 0.031, OR
1.61 respectively). Another variant rs4986910 (CYP3A4,
T > C) correlated with thrombocytopenia grade 3–4, be-
fore and after correction for relevant covariates (p = 0.012,
OR 5.61 and p = 0.025, OR 4.99 respectively; Table 3).
Table 1 Overview of the 26 genotyped single nucleotide polymorphisms (SNPs)
Gene Name Function of the gene
product
Variant allele (rs number,
nucleotide, amino acid change)
Effect of the polymorphism on
the toxicity or clinical outcome




efflux of cytotoxic agents
rs1128503, c.1236C>T, Gly412Gly Homozygous carriers of the variant
allele: docetaxel clearance decreased [9].
rs1045642, c.3435C>T, Ile1145Ile Variant allele carriers: more pronounced
neutrophil depression following treatment
with paclitaxel ± carboplatin [18] and
increased AUC of the paclitaxel
metabolite 3′-p-hydroxypaclitaxel [8].
Homozygous carriers of the variant
allele: decreased risk of neutropenia
and neurotoxicity [11]
No correlation was found with
pharmacokinetics, toxicity or outcome
in OC patients in different other studies
[9,10,12,13,15,17].
rs2229109,c.1199G>A, Ser400Asn Variant allele carriers: correlation with





efflux of cytotoxic drugs
rs2230671, c.4002G>A, Ser1334Ser In vitro evidence: over-expression of
ABCC1 protein has been associated
with a low degree of resistance to
paclitaxel [23].
rs2074087, c.2284-30G>C No correlation of variants in rs2230671
and rs2074087 with toxicity and outcome






efflux of cytotoxic drugs
rs2073337, c.1668+148A>G In vitro evidence: paclitaxel and docetaxel
are ABCC2 substrates in cell lines [24]. No
correlation was found with toxicity or
treatment outcome with platinum-taxane
treatment in OC patients [12,17].
rs12762549, g.101620771C>G Variant allele carriers from Japan: increased
risk for severe neutropenia following
treatment with docetaxel [19].
ABCG2 ATP-binding cassette
sub-family G member 2
ATP binding membrane
transporter implicated in
efflux of cytotoxic drugs
rs2231142, c.421C>A, Gln141Lys Variant allele carriers in OC: 6-month
longer median PFS following platinum/
taxane-based chemotherapy [17].
ABCA1 ATP-binding cassette
sub-family A member 1
ATP binding membrane
transporter, efflux pump
for S1P and cholesterol
rs363717, c.*1896 A>G Variant allele carriers: decreased risk on
thalidomide related neuropathy grade
≥2 [36].





the transport of cytotoxic
drugs
rs4149117, 334T>G, Ser112Ala Docetaxel and paclitaxel transport by
SCLO1B3-expressing oocytes was
higher compared to controls
in vitro [20].
rs11045585, c.1683-5676A>G Variant allele carriers from Japan: increased
docetaxel induced leukopenia/neutropenia
[19], higher docetaxel clearance and lower
AUC in nasopharyngeal carcinoma
patients [21].
CYP1B1 Cytochrome P450
family 1, subfamily B,
polypeptide 1







Homozygous carriers of the wild-type
allele: decreased risk of grade 3/4
gastro-intestinal toxicity in docetaxel
treated OC patients in the development
but not in the validation set [12].
CYP3A4 Cytochrome P450,
family 3, subfamily A,
polypeptide 4







CYP3A4 activity determined the dominant
metabolic pathway for paclitaxel [14].
Homozygous carriers of the variant allele:
decreased clearance of docetaxel [26].
Homozygous carriers of the variant allele:
increased risk of invasive OC [27].
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Table 1 Overview of the 26 genotyped single nucleotide polymorphisms (SNPs) (Continued)
rs4986910, c.1331T>C, Met444Thr
(CYP3A4*3)
No correlation with pharmacokinetics,
toxicity or outcome in OC patients
treated with carboplatin + paclitaxel
or docetaxel [9,10,12].
CYP3A5 Cytochrome P450,
family 3, subfamily A,
polypeptide 5





rs776746, c.219-237G>A Homozygous carriers of the variant
allele: increased neurotoxicity following
paclitaxel treatment 25. No correlation
with pharmacokinetics, toxicity or outcome
in OC patients treated with carboplatin +
paclitaxel or docetaxel [9,10,12].





rs1042522, c.215C>G, Pro72Arg Associated with a small increase in risk
of OC [29], twofold increased risk of OC
in proline carriers and a longer
progression-free survival in homozygous
arginine allele carriers [28]. Homozygous
carriers of the variant allele: increased






rs11568305, c.215C>G, Pro587= No correlation with toxicity or outcome
in OC patients treated with carboplatin +




involved in the prevention
of platinum-based DNA
damage
rs1695, c.313A>G, Ile105Val Variant allele carriers: decreased
oxaliplatin-related neuropathy [30],
decreased docetaxel-induced grade 2
neuropathy [31], decreased risk of
hematologic toxicity [15].
rs1138272, c.341 C>T, Ala114Val Variant allele carriers compared to
homozygous carriers of the wild-type
allele: decreased PFS following
cisplatin-gemcitabine [32].
In other studies, no association with
toxicity in OC patients [12,32].






rs11615, c.354T>C, Asn118Asn Variant allele carriers: decreased
platinum resistance [34].
rs3212961, 17677G>T Variant allele carriers compared to
homozygous carriers of the wild-type
allele: increased risk on severe neutropenia
and increased likelihood of overall survival
following cisplatin-gemcitabine [32].
No correlation for both genetic
variants with toxicity/outcome for
OC patients [12].






rs1799793, c.934G>A, Asp312Asn Variant allele carriers: increased severity
of neutropenia in OC patients receiving
cisplatin-cyclophosphamide [33].








Variant allele carriers: decreased risk on
thalidomide related neuropathy grade
≥2 [36].
SERPINB2 Serpin peptidase





rs6104, 1238C>G, Ser413Cys Variant allele carriers: decreased risk on





playing a role in
neuro-inflammation
rs2076169, T>C Variant allele carriers: decreased risk on







rs1799969, 241G>A Variant allele carriers: decreased risk on
thalidomide related neuropathy grade
≥2 [36].
The following 7 genetic variants failed genotyping: rs2032582 (Ser893Ala in ABCB1), rs2273697 (Val417Ile in ABCC2), rs1058930 (Ile194Met in CYP2C8), rs11572080
(Arg69Lyes in CYP2C8), rs10509681 (Lys329Arg in CYP2C8), rs12721627 (Thr185Ser in CYP3A4), rs25487 (Gln398Arg in XRCC1). Rs6103 was replaced by rs6104
because these were in full linkage disequilibrium (r2 = 1.0). OC: ovarian cancer, NSCLS: non-small-cell lung carcinoma.
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Table 2 Patient and disease characteristics, hematologic and neuro-toxicity characteristics
Patient and disease characteristics
Total Number of
patients recruited
Population for hematologic analysis Population for outcome
N=322 All patients Paclitaxel-Carboplatin Carboplatin N=266
N=290 N=240 N=50
Age at diagnosis (years) p=0.188* p=0.218§ p=0.128*
Median 60 59 59 56 59
Range (20-85) (20-85) (21-82) (20-85) (21-84)
Body mass index (BMI) p=0.863* p=0.063§ p=0.055*
Median 25 25 24 26 24
Range (16-39) (16-39) (16-39) (18-37) (16-39)
Race p=0.951* p=0.517§ p=0.520*
Caucasian 319 (99%) 287 (99%) 238 (99%) 49 (98%) 264 (99%)
African 1 (<1%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%)
Asian 1 (<1%) 1 (<1%) 1 (<1%) 0 (0%) 1 (<1%)
Mixed: Asian-Indo-European 1 (<1%) 1 (<1%) 1 (<1%) 0 (0%) 1 (<1%)
Histologic subtype p=0.532* p<0.001§ p<0.001*
Serous 258 (80%) 230 (79%) 209 (87%) 21 (42%) 231 (87%)
Mucinous 20 (6%) 19 (7%) 5 (2%) 14 (28%) 6 (2%)
Endometrioid 13 (4%) 13 (4%) 5 (2%) 8 (16%) 5 (2%)
Clear cell 17 (5%) 14 (5%) 8 (3%) 6 (12%) 11 (4%)
Mixed cell 8 (3%) 8 (3%) 7 (3%) 1 (2%) 7 (3%)
Other epithelial ovarian cancer 3 (1%) 3 (1%) 3 (1%) 0 (0%) 3 (1%)
Non-epithelial 3 (1%) 3 (1%) 3 (1%) 0 (0%) 3 (1%)
FIGO stage p=0.645* p<0.001§ p<0.001*
I 55 (15%) 52 (18%) 11 (5%) 41 (82%) 14 (5%)
II 17 (5%) 15 (5%) 13 (5%) 2 (4%) 15 (6%)
III 196 (61%) 175 (60%) 169 (70%) 6 (12%) 184 (69%)
IV 54 (17%) 48 (17%) 47 (20%) 1 (2%) 53 (20%)
Tumor grade p=0.235* p<0.001§ p<0.001*
1 23 (7%) 23 (8%) 13(5%) 10 (20%) 13 (5%)
2 50 (16%) 45 (16%) 30 (12%) 15 (30%) 35 (13%)
3 249 (77%) 222 (77%) 197 (82%) 25 (50%) 218 (82%)
Residual disease p=0.120* p<0.001§ p=0.424*
No macroscopic disease 267 (83%) 246 (85%) 200 (83%) 46 (92%) 218 (82%)
Macroscopic disease < 1cm 7 (2%) 6 (2%) 6 (3%) 0 (0%) 7 (3%)
Macroscopic disease > 1 cm 8 (3%) 6 (2%) 6 (3%) 0 (0%) 8 (3%)
Macroscopic disease, size unknown 5 (2%) 4 (1%) 3 (1%) 1 (2%) 4 (2%)
Macroscopic disease, inoperable 35 (11%) 28 (10%) 25 (10%) 3 (6%) 29 (11%)
Hematologic toxicity characteristics
All patients Paclitaxel-Carboplatin Carboplatin
(N= 290) (N=240) (N=50)
Number of cycles administered p=0.266§
<6 15 (5%) 14 (6%) 1 (2%)
6 275 (95%) 226 (94%) 49 (98%)
Lambrechts et al. BMC Pharmacology and Toxicology  (2015) 16:2 Page 6 of 13
Table 2 Patient and disease characteristics, hematologic and neuro-toxicity characteristics (Continued)
Grade anemia p=0.118§
0/1 62 (21%) 51 (21%) 11 (22%)
2 171 (59%) 136 (57%) 35 (70%)
3 51 (18%) 48 (20%) 3 (6%)
4 6 (2%) 5 (2%) 1 (2%)
Use of Erythropoiesis stimulating Agent (ESA) p=0.073§
No 220 (76%) 187 (78%) 33 (66%)
Yes 70 (24%) 53 (22%) 17 (34%)
Grade neutropenia p<0.001§
0/1 19 (7%) 9 (4%) 10 (20%)
2 14 (5%) 3 (1%) 11 (22%)
3 55 (19%) 32 (13%) 23 (46%)
4 202 (70%) 196 (82%) 6 (12%)
Febrile neutropenia p=0.740§
0 267 (92%) 217 (90%) 50 (100%)
3 22 (8%) 22 (9%) 0 (0%)
4 1 (<1%) 1 (<1%) 0 (0%)
Use of colony stimulating factor (CSF) p<0.001§
No 228 (79%) 178 (74%) 50 (100%)
Yes 62 (21%) 62 (26%) 0 (0%)
Grade Trombocytopenia p=0.089§
0/1 180 (62%) 156 (65%) 24 (48%)
2 53 (18%) 41 (17%) 12 (24%)
3 43 (15%) 31 (13%) 12 (24%)
4 14 (5%) 12 (5%) 2 (4%)
Neurotoxicity characteristics
Population for neurotoxicity analysis
(Paclitaxel-Carboplatin) (N=265)
Population excluded for neurotoxicity
(Carboplatin) (N=56)
Number of cycles administered p=0.596#
<6 18 (7%) 2 (4%)
6 247 (93%) 54 (96%)
Grade peripheral sensory neuropathy p<0.001#
0 109 (41%) 48 (86%)
1 108 (41%) 6 (11%)
2 39 (15%) 1 (2%)
3 9 (3%) 0 (0%)
Grade motor neuropathy p=0.461#
0 56 (100%) 254 (96%)
1 0 (0%) 10 (4%)
2 0 (0%) 1 (<1%)
3 0 (0%) 0 (0%)
4 0 (0%) 0 (0%)
*: p-value calculated against the total population (n = 322), §: p-value calculated against the population for hematologic analysis treated with taxol-carboplatin
(n = 240), #: p-value calculated against the population for neurotoxicity treated with taxol-carboplatin (n = 265).
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tropenia and febrile neutropenia, we did not observe a sig-
nificant association. Finally, we also correlated each of thevariants to sensory neuropathy in the population that was
eligible for neurotoxicity analyses, but failed to identify
significant associations. None of the observed associations
Table 3 Association between genetic variants and hematologic toxicity
3A: Significant correlations with anemia
All patients
N = 290 (%)
Patients with anemia
gr 3–4 N= 57 (19.6%)
Patients without anemia







ABCB1 rs1128503 CC 94 (32.4) 13 (22.8) 81 (34.8) 1.58 (1.03; 2.42) 0.035 1.71 (1.07; 2.71) 0.023
CT 147 (50.7) 30 (52.6) 117 (50.2)
TT 49 (16.9) 14 (24.6) 35 (15.0)
ABCC2 rs12762549 CC 80 (27.6) 25 (43.8) 55 (23.6) 0.55 (0.36; 0.83) 0.005 0.51 (0.33; 0.81) 0.004
CG132 (45.5) 22 (38.6) 110 (47.2)
GG 76 (26.2) 10 (17.5) 66 (28.3)
ABCA1 rs363717 AA 86 (29.6) 10 (17.5) 76 (32.6) 1.31 (1.98; 2.99) 0.001 2.08 (1.32; 3.27) 0.002
GA 131 (45.2) 23 (40.3) 108 (33.5)
GG 73 (25.2) 24 (42.1) 49 (15.2)
ERCC1 rs11615 TT 133 (45.9) 18 (31.6) 115 (49.3) 1.58 (1.06-2.35) 0.024 1.61 (1.04-2.50) 0.031
TC 114 (39.3) 28 (49.1) 86 (36.9)
CC 42 (14.5) 11 (19.3) 31 (13.3)
3B: Significant correlations with thrombocytopenia (TCP)
All patients Patients with
TCP gr 3 – 4
Patients without
TCP gr 3 – 4
Unadjusted OR *p-value Adjusted OR **Corrected
p value
N = 290 (%) N = 57 (19.6%) N = 233 (80.3%) (95%CI) (95% CI)
CYP3A4 rs4986910 TT 280 (96.5) 51(89.5) 229(98.3) 5.61 (1.46; 21.64) 0.012 4.99 (1.22; 20.31) 0.025
CT 9 (3.1) 5(8.8) 4(1.7)
CC 0 (0) 0 0
OR: Odds Ratio using wild type as reference category. *Uncorrected p values were calculated using binary logistic regression without correction for covariates. Per-allele ORs
and 95% CIs are shown. There were missing genotypes for rs12762549 (n = 2), rs11615 (n = 1) and rs4986910 (n = 1). **Corrected p values were obtained using a logistic
regression for the presence or absence of anemia/thrombocytopenia/febrile neutropenia while including the following covariates: genetic variant, age, BMI, AUC of
carboplatin, number of administered cycles, and use of ESA for anemia or use of CSF for febrile neutropenia. In the regression for anemia, age, BMI, administered AUC of
carboplatin or number of administered cycles were not identified as significant covariates (p = 0.576, p = 0.614 and p = 0.317, p = 0.481), whereas use of ESA was
significant (p = 0.034). In the regression for grade 3–4 thrombocytopenia, age and AUC of administered carboplatin were a significant covariate (p = 0.023 and
p = 0.014), but BMI or number of administered cycles were not (p = 0.571 and p = 0.243). In the regression for grade 4 neutropenia, BMI and age were significant
covariates (p = 0.043 and p = 0.041), while administered AUC and number of administered cycles were not (p = 0.607 and p = 0.321).
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testing.
Association between genetic variants and use of growth
factors
The use of ESAs or CSFs was also correlated with each of
the 26 variants to examine whether they could predict the
need for an ESA or CSF during treatment with chemother-
apy in ovarian cancer. After correction for relevant covari-
ates, a significant correlation for rs2074087 (ABCC1, G >C)
and the use of ESA was noticed (p = 0.011, OR 2.09,
Table 4). After correction for covariates, CSF use was sig-
nificantly correlated with rs2073337 (ABCC2, A >G),
rs1695 (GSTP1, A >G) and rs1799793 (ERCC2, G >A) (p =
0.039, OR 0.60; p = 0.017, OR 0.55; and p = 0.042, OR 0.63
respectively). None of the observed associations with use of
growth factors survived correction for multiple testing.
Effects of variants on PFI and OS
The median follow-up of all patients participating to the
study was 2.5 years (95% CI = 2.2-2.8 years) with 157events for progression (59%) and 84 events for OS
(31.6%). Uncorrected P-values were calculated using Cox
regression analysis either adjusted for age at diagnosis
only or fully adjusted for age at diagnosis, FIGO stage,
tumor grade, tumor histology and residual disease after
debulking surgery. Only one variant, rs1799793 (ERCC2
G > A), was significantly correlated with PFI in both
cases (p = 0.003, HR = 0.71, 95% CI = 0.57-0.89, p =
0.016, HR = 0.75, 95% CI = 0.60-0.95). In particular,
Kaplan-Meier survival analysis revealed a significant
advantage in PFI for GG carriers of rs1799793 com-
pared to AA or GA carriers (p = 0.016; Figure 1).
Variants rs12762549 (ABCC2 A > G) and rs6104 (SER-
PINB2 C > G) were significantly associated with PFI in
the fully-adjusted model (p = 0.037 and p = 0.040, re-
spectively), but these associations were not statistically
significant in model adjusted for age only (p = 0.402
and p = 0.219, respectively). No significant correlations
were found for OS.
None of the observed associations with platinum-free
interval survived correction for multiple testing.
Table 4 Association between genetic variants and erythropoiesis stimulating agents (ESA) or colony stimulating factor
(CSF) use
4A: Significant correlations with ESA use










N = 290 (%) N = 70 (24.2%) N = 219 (75.8%)
ABCC1 rs2074087 GG 215 (74.4) 46 (65.7) 169 (77.2) 1.78 (1.03- 3.08) 0.054 2.09 (1.18 - 3.68) 0.011
GC 69 (23.9) 22 (31.4) 47 (21.5)
CC 5 (1.7) 2 (2.8) 3 (1.4)
4B: Significant correlations with CSF use




Unadjusted OR *p-value Adjusted OR **Corrected
p value
N = 290 (%) N = 62 (21.4%) N = 228 (78.6%) (95%CI) (95% CI)
ABCC2 rs2073337 AA 101 (34.8) 27 (43.5) 74 (32.5) 0.61 (0.39- 0.96) 0.031 0.60 (0.37-0.99) 0.039
AG 148 (51.0) 31 (50.0) 117 (51.3)
GG 41 (14.1) 4 (6.5) 37 (16.2)
GSTP1 rs1695 AA 121 (41.7) 33 (53.2) 88 (38.6) 0.54 (0.34; 0.86) 0.010 0.55 (0.33-0.90) 0.017
AG 137 (47.2) 27 (43.5) 110 (48.2)
GG 32 (11.0) 2 (3.2) 30 (13.2)
ERCC2 Rs1799793 GG 136 (48.2) 21 (33.9) 115 (50.4) 0.67 (0.45- 1.00) 0.048 0.63 (0.41-0.98) 0.042
GA 111 (39.4) 30 (48.4) 81 (35.5)
AA 35 (12.4) 9 (14.5) 26 (11.4)
OR: Odds Ratio using wild type as reference category. *Uncorrected p values were calculated using binary logistic regression for the need for ESA/CSF use without
correction for covariates. Per-allele ORs and 95% CIs are shown. There were missing genotypes for rs2074087 (n = 1), rs1799793 (n = 8). **Corrected p values were
obtained using a logistic regression for the need for ESA/CSF use while including the following covariates: genetic variants, age, BMI, dosage of carboplatin (AUC)
and number of administered cycles.
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We correlated paclitaxel- and carboplatin-induced tox-
icity with genetic variation in genes involved in pharma-
cokinetics of these chemotherapeutics or DNA repair,
and observed various correlations supporting a role forFigure 1 Kaplan-Meier curve for platinum-free interval correlated
with polymorphisms of rs1799793 in ERCC2. Kaplan-Meier survival
analysis reveales a significant advantage in PFI for GG cariers of
rs1799793 compared to AA or GA carriers (p = 0.016).these genes in mediating toxicity and therapy outcome.
We observed that several variants correlated either with
grade ≥3 anemia or thrombocytopenia, use of CSFs or
ESAs, as well as the platinum-free interval (see Table 5
for an overview of all significant associations). These
variants are located in genes that play an important role
in transport (ABCB1, ABCC2, ABCC1, ABCA1) and
hepatic metabolism (CYP3A4) of paclitaxel and base-
excision repair of platinum-induced DNA damage
(ERCC1, ERCC2), thus confirming a role for these genes
in mediating side-effects and efficacy of paclitaxel and
carboplatin. Indeed, ATP-binding cassette transporters,
which are expressed on the cell-membrane surface, play
an important role in the transport of taxanes [39],
whereas cytochrome P450 proteins, CYP2C8, CYP3A4
and CYP3A5, catalyze the oxidative metabolism of tax-
anes. Furthermore, ERCC1 and ERCC2 are subunits of
the endonuclease complex that plays an essential role in
DNA repair by removing platinum-induced intra-strand
cross-links.
Most other studies assessing similar correlations have
been performed in smaller populations, and typically
evaluated only few variants. Our study evaluates a more
systematically-selected panel of 26 variants in a large
population of ovarian cancer patients, of which 290
were evaluable for hematologic toxicity and 265 for
Table 5 Overview of all significant correlations per genetic variant
Gene Variant allele (rs number,
nucleotide)
Effect of the variant allele on
toxicity or outcome
Corrected p value,
adjusted OR, 95% CI
Effect of the polymorphisms
according to the literature
ABCB1 rs1128503 c.1236C > T Increased risk anemia grade 3-4 p = 0.023; Homozygous mutant allele carriers:
decreased doctaxel clearance in 92
patients 9OR 1.71, 1.07 – 2.71
ABCC2 rs12762549 g.101620771C > G Decreased risk anemia grade 3-4 p = 0.004; Japanese mutant allele carriers:
increased risk for severe neutropenia
during treatment with docetaxel in
84 patients19
OR 0.51, 0.33-0.81
rs2073337 c.1668 + 148A > G Decreased need for colony
stimulating factor
p = 0.039; In vitro evidence: paclitaxel is a
substrate of ABCC224
OR 0.60, 0.37-0.98
ABCC1 rs2074087 c.2284-30 G > C Increased need for erythropoiesis
stimulating agent
p = 0.011; In vitro evidence: resistance to
paclitaxel with ABCC1
overexpression23OR 2.09, 1.18-3.68
ABCA1 rs363717 c.1896 A > G Increased risk anemia grade 3-4 p = 0.002; Mutant allele carriers: decreased risk
to develop thalidomide related
neuropathy grade ≥2 in 1495
patients 36
OR 2.08, 1.32-3.27
CYP3A4 rs4986910 c.1331 T > C Increased risk thrombocytopenia
grade 3-4
p = 0.025; -
OR 4.99, 1.22-20.31
GSTP1 rs1695 c.313A > G Decreased need for colony
stimulating factor
p = 0.017; Mutant allele carriers: decreased
oxaliplatin-related neuropathy in 90
patients30, decreased docetaxel-
induced grade 2 neuropathy in 58
patients31, decreased risk of
hematologic toxicity in 118 patients15
OR 0.55, 0.33-0.90
Heterozygous mutant allele carriers
compared to homozygous wildtype
allele carriers: decreased PFS following
cisplatin-gemcitabine in 104 patients 32
ERCC1 rs11615 c.354 T > C Increased risk anemia grade 3-4 p = 0.031; Mutant allele carriers: decreased
platinum resistance in 60 patients34
OR 1.61, 1.04-2.50
Heterozygous variant allele carriers
compared to homozygous wildtype
allele carriers: increased risk on severe
neutropenia and increased likelihood
of overall survival following cisplatin-
gemcitabine in 104 patients32
ERCC2 rs1799793 c.934G > A Decreased need for colony
stimulating factor
p = 0.042; Heterozygous variant allele carriers
compared to homozygous wildtype
allele carriers: increased severity of
neutropenia following cisplatin-
cyclophosphamide in 104 patients32
OR 0.63, 0.41-0.98
Decreased platinum free interval p = 0.016,
HR = 0.75, 0.60-0.95
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availability of more detailed clinical toxicity data com-
pared to previous pharmacogenetic association studies
in ovarian cancer, allowing us to correlate specific en-
tities of the hematologic toxicity spectrum, whereas
other studies mostly grouped all hematologic > grade 3
toxicities into a single group [8,12,14,15] or focused on
the occurrence of neutropenia alone [11,18].
Several of the previously published studies investigating
the role of these variants with respect to toxicity and
chemotherapy outcome confirmed the observations made
in the present study. With respect to the ABC trans-
porters, the rs1128503 (1236C > T) synonymous variant inABCB1 has been associated with multidrug resistance in
multiple studies, and with decreased docetaxel clearance
in particular, for homozygous carriers of the variant
T-allele in 92 patients [9]. However, its association
with severe anemia observed in our study has not been re-
ported before. The rs1045642 (3435C > T) synonymous
variant in ABCB1 increased 3′p-hydroxy-paclitaxel metab-
olites in 23 ovarian cancer patients carrying the T-allele
[8]. Vice versa, in a study of 26 patients, a significant
greater percent decrease in absolute neutrophil count
at nadir was reported for patients homozygous for the
T-allele [11], Bergmann also reported a more pro-
nounced neutrophil decrease in patients carrying the
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[18]. In our study, we failed to observe an association with
grade ≥3 neutropenia or febrile neutropenia. Possibly, this
is due to the fact that we analyzed grade ≥3 neutropenia
whilst previous studies used absolute neutrophil decrease.
A Japanese study demonstrated that carriers of the variant
allele for rs12762549 (ABCC2,101620771 C >G) had an
increased risk to develop docetaxel-induced leukopenia/
neutropenia in 84 patients [19]. In the current study, no
such association was found, but we did find a significant
association with anemia and PFI, thereby confirming the
potential importance of this variant in mediating taxane
transport. Notably, another variant in this gene, rs2073337
(1668 + 148A >G), was significantly correlated with CSF
use. For rs363717 (1896 A >G) in ABCA1, which was se-
lected based on its association with thalidomide-related
peripheral neuropathy [36], we did not observe a signifi-
cant association with sensory neurotoxicity. We observed,
however, a significant association of this variant with
severe anemia (p = 0.001), suggesting that ABCA1 is in-
volved in the transport and metabolism of platinum or
carboplatin, similar to its role in the transport of choles-
terol [40].
With respect to the CYP genes, low CYP3A4 enzyme
activity increased the conversion of paclitaxel towards its
metabolite, while heterozygous patients for CYP2C8*3
had a lower clearance of paclitaxel, suggesting the role
of those genes in paclitaxel pharmacokinetics in a study
of 38 patients [14]. In 93 patients with ovarian cancer,
Bergmann et al. observed an 11% reduction in paclitaxel
clearance in carriers of the rs10509681 (1196A >G) vari-
ant G-allele in CYP2C8 [16], whereas Leskelä et al. ob-
served a correlation between neurotoxicity and these
CYP2C8 and CYP3A5 variants in a study consisting of 118
patients [25]. In the present study, we failed however, to
observe such associations. Another large study in ovarian
cancer also failed to observe correlations with neurotox-
icity for these variants in docetaxel or paclitaxel-treated
patients [12]. We did observe, however, a significant asso-
ciation between rs4986910 (1331 T > C) in CYP3A4 and
thrombocytopenia. Homozygous carriers of the rs1695
(313A >G) variant G-allele in GSTP1 have been associated
with neuropathy in 90 patients receiving oxaliplatin-based
chemotherapy [30]. This association was not confirmed in
our study, although a correlation with febrile neutropenia
and CSF use was observed.
Finally, with respect to the excision repair genes, pre-
vious studies reported a correlation between severe
neutropenia and the rs1799793 (934G > A) variant A-
allele in ERCC2 in 104 ovarian cancer patients receiving a
cisplatin-cyclophosphamide regimen [32]. In the current
study, no correlation with severe neutropenia was de-
scribed, although the rs1799793 (934G >A) variant A-allele
did correlate significantly with CSF use during treatment.Additionally, we observed an improved PFI for rs1799793
(934G >A) GG-carriers. The largest study to date exploring
the association between 27 selected variants and ovarian
cancer survival, which was performed by the ovarian cancer
association consortium (OCAC) in >10,000 cases [41],
rs1799793 (934G >A) was not tested. Nevertheless, in the
high-grade serous sub-population of this large study, a sig-
nificant correlation was found with another variant in
ERCC2 (rs50872 A >G) and outcome, confirming the po-
tential importance of ERCC2 in mediating chemotherapy
outcome. Unfortunately, rs50872 was not linked with
rs1799793 (934G >A) (r2 = 0.06), indicating that these vari-
ants represent different association signals with ERCC2.
In summary, we observed the strongest associations
between variants in ABC-transporters and anemia. The
mechanism explaining why altered transport of cytotoxic
chemotherapy affects erythropoiesis rather than granulo-
poiesis or thrombopoiesis is not yet understood. Possibly,
these variants alter intracellular concentrations of the
transported cytotoxic drug in a cell type-specific manner.
Another possibility is that some cell types might be more
sensitive to specific changes in the concentration of cer-
tain metabolites. On the other hand, it is also possible that
the effect on erythropoiesis is caused by a specific role of
the affected gene during erythropoiesis. For example, a
prominent role for ABCB6 during erythropoiesis as a
mitochondrial porphyrin transporter essential for heme
biosynthesis, has been established [42].
It is a limitation of the current study that the group
for hematologic toxicity analysis included both single
agent carboplatin as paclitaxel/carboplatin combination
therapy although it is known that both regimens have a
slightly different hematologic toxicity profile with more
thrombocytopenia in carboplatin monotherapy com-
pared to combination regimens, in our cohort the rate
of grade 3–4 thrombocytopenia was 28% for carboplatin
versus 18% for combination therapy. Apart from the fact
that both regimens are included for hematologic ana-
lysis, this cohort is relatively homogenous including only
data on first-line treatment in ovarian cancer patients
with a uniform ethnicity (99% Caucasians), high number
of optimal debulked patients and relatively uniform
number of administered cycles of chemotherapy. To fur-
ther reduce the problem of heterogeneity, pharmacoge-
netic research on prospective clinical trials including large
populations of uniformly treated patients is warranted.
It should be noted that the candidate-gene approach
employed so far selecting drug-related genes derived
from platinum/taxane pharmacology only allows the
analysis with candidate genes known to be involved in
chemotherapy metabolism, transport or DNA repair. To
discover novel genetic markers, other approaches such
as whole-genome association studies or targeted re-
sequencing of strong candidate genes to identify rare
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drug- or toxicity -related candidate genes relevant for
paclitaxel-carboplatin treatment in ovarian cancer (such
as GSTA-1 [32], MAD1L1 [43], OPRM1 [44], TRPV1
[44], …) could be selected based on pharmacogenetic
knowledge bases such as pharmGKB (www.pharmgkb.
org).
Conclusions
The current study revealed a correlation between SNPs
in genes involved in DNA repair or metabolism or
transport of taxanes or platinum and toxicity or re-
sponse to first-line chemotherapy in ovarian cancer,
using a candidate-gene approach. Variants reported in
this study may serve as biomarkers and contribute to
the clinical decision-making of chemotherapy dose re-
ductions, feasibility of chemotherapy in patients at-risk
based on age and/or performance status, and use of
supportive medication such as ESA or CSF. However,
as none of the identified associations survived correction
for multiple testing, our data are only hypothesis-
generating and still need independent validation. We plan
to perform such a validation by performing genome-wide
screens or targeted re-sequencing of candidate genes in a
large multi-centered clinical trial.
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